Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6810675 | 0.99 | BRD4 (0.45) | MAOAMAOBTDP1BRD4CA12 | |
| SCHEMBL6811830 | 0.92 | BRD4 (0.40) | MAOAMAOBTDP1BRD4CA12 | |
| SCHEMBL5972486 | 0.91 | MAOA (0.46) | MAOAMAOBTDP1BRD4CA12 | |
| SCHEMBL5972545 | 0.90 | MAOA (0.44) | MAOAMAOBTDP1BRD4CA12 | |
| SCHEMBL5972544 | 0.83 | CA1 (0.40) | MAOAMAOBTDP1BRD4CA12 | |
| SCHEMBL337290 | 0.83 | IDO1 (0.39) | TDP1BRD4GAABCHE | |
| SCHEMBL6810672 | 0.81 | SIGMAR1 (0.44) | TDP1BRD4CA12CA1CA2 | |
| SCHEMBL7135619 | 0.79 | EPHX2 (0.36) | EPHX2NR1H4MEN1KMT2ABCHE | |
| SCHEMBL15862351 | 0.77 | EPHX2 (0.51) | BRD4EPHX2NR1H4 | |
| SCHEMBL1495902 | 0.76 | EPHX2 (0.64) | BRD4EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014964-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6548663-B1 | Imaging tumors and cancer with radioisotope benzodiazepine metal complex as contrast agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014964-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | MAOA 3396/4885MAOB 2431/4885TDP1 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.